Executive summary

This study from Taiwan retrospectively examined 30 patients with unresectable CC who were treated with PBT to a total dose of 72.6 GyRBE. The 1-year local control, regional control, and distant metastases-free rates were 88%, 86%, and 68%, respectively. The median overall survival and progression-free survival were 19.3 and 10.4 months.

The most common acute toxicity was acute skin reactions which were rarely severe (grade III: 7% of patients). Three and 2 patients had grade III-IV toxicities and radiation-induced liver disease. There were no deaths caused by PBT or concurrent chemotherapy. The authors concluded that PBT is clinically useful in patients with unresectable CC.
 

Key content topics
Top cancer treatments